Back to Search Start Over

SIRT1 Promotes Chemoradiotherapy Resistance in Esophageal Squamous Cell Carcinoma.

Authors :
Morishita H
Otsuka R
Murakami K
Endo S
Toyozumi T
Matsumoto Y
Shiraishi T
Iida S
Makiyama T
Nishioka Y
Hu J
Maiyulan A
Matsubara H
Source :
Oncology [Oncology] 2024; Vol. 102 (11), pp. 960-968. Date of Electronic Publication: 2024 Jul 22.
Publication Year :
2024

Abstract

Introduction: Identifying accurate biomarkers for predicting response to chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC) is a critical challenge. The protein SIRT1, recognized for its implications in longevity, has been associated with tumor promotion in ESCC. However, data regarding its correlation with CRT sensitivity remain unreported. Therefore, in this study, we aimed to investigate the relationship between SIRT1 expression and CRT sensitivity and concurrently assess the effect of SIRT1 knockdown on CRT sensitivity in ESCC.<br />Methods: This study included 73 patients who underwent radical esophagectomy after CRT. SIRT1 expression in pre-treatment endoscopic biopsies was assessed through immunostaining, followed by a comparative analysis of CRT effects on surgical specimens. Small interfering RNA was used to attenuate SIRT1 expression in TE5 and TE10 cells, which were then subjected to cisplatin treatment at varying doses and concentrations and irradiation with X-rays, respectively.<br />Results: High SIRT1 tissue expression was significantly associated with CRT resistance. Multivariate analysis identified high SIRT1 expression as an independent biomarker for poor CRT response. In TE-5 and TE-10 cells, SIRT1 knockdown significantly decreased cell viability and increased sensitivity to cisplatin and radiation treatment compared to that of the negative control.<br />Conclusion: Our study results demonstrate the potential of SIRT1 as a predictive biomarker for CRT response in ESCC, highlighting the heightened sensitivity to CRT upon the transcriptional inactivation of SIRT1. Targeting SIRT1 emerges as a promising strategy for enhancing the efficacy of CRT for ESCC.<br /> (© 2024 S. Karger AG, Basel.)

Details

Language :
English
ISSN :
1423-0232
Volume :
102
Issue :
11
Database :
MEDLINE
Journal :
Oncology
Publication Type :
Academic Journal
Accession number :
38972308
Full Text :
https://doi.org/10.1159/000540247